These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22676711)

  • 1. Pharmacogenomics of warfarin in populations of African descent.
    Suarez-Kurtz G; Botton MR
    Br J Clin Pharmacol; 2013 Feb; 75(2):334-46. PubMed ID: 22676711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications.
    Suarez-Kurtz G; Amorim A; Damasceno A; Hutz MH; de Moraes MO; Ojopi EB; Pena SD; Perini JA; Prata MJ; Ribeiro-dos-Santos A; Romano-Silva MA; Teixeira D; Struchiner CJ
    Pharmacogenomics; 2010 Sep; 11(9):1257-67. PubMed ID: 20860466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of warfarin dosing in patients of African and European ancestry.
    Shendre A; Dillon C; Limdi NA
    Pharmacogenomics; 2018 Nov; 19(17):1357-1371. PubMed ID: 30345882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of coumarin anticoagulants in Brazilians.
    Suarez-Kurtz G; Botton MR
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):67-79. PubMed ID: 25345887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
    Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
    J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.
    Sridharan K; Al Banna R; Malalla Z; Husain A; Sater M; Jassim G; Otoom S
    Pharmacol Rep; 2021 Oct; 73(5):1405-1417. PubMed ID: 33811620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
    Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
    Asiimwe IG; Zhang EJ; Osanlou R; Krause A; Dillon C; Suarez-Kurtz G; Zhang H; Perini JA; Renta JY; Duconge J; Cavallari LH; Marcatto LR; Beasly MT; Perera MA; Limdi NA; Santos PCJL; Kimmel SE; Lubitz SA; Scott SA; Kawai VK; Jorgensen AL; Pirmohamed M
    Clin Pharmacol Ther; 2020 Jun; 107(6):1420-1433. PubMed ID: 31869433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort.
    Perini JA; Struchiner CJ; Silva-Assunção E; Suarez-Kurtz G
    Clin Pharmacol Ther; 2010 Apr; 87(4):417-20. PubMed ID: 20182420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy.
    Orsi FA; Annichino Bizzacchi JM; de Paula EV; Ozelo MC; Langley MR; Weck KE
    Thromb Res; 2010 Sep; 126(3):e206-10. PubMed ID: 20615525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic versus clinical dosing of warfarin in individuals of Chinese and African-American ancestry: assessment using data simulation.
    Syn NL; Lee SC; Brunham LR; Goh BC
    Pharmacogenet Genomics; 2015 Oct; 25(10):491-500. PubMed ID: 26230382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
    Limdi NA; Wadelius M; Cavallari L; Eriksson N; Crawford DC; Lee MT; Chen CH; Motsinger-Reif A; Sagreiya H; Liu N; Wu AH; Gage BF; Jorgensen A; Pirmohamed M; Shin JG; Suarez-Kurtz G; Kimmel SE; Johnson JA; Klein TE; Wagner MJ;
    Blood; 2010 May; 115(18):3827-34. PubMed ID: 20203262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
    Drozda K; Wong S; Patel SR; Bress AP; Nutescu EA; Kittles RA; Cavallari LH
    Pharmacogenet Genomics; 2015 Feb; 25(2):73-81. PubMed ID: 25461246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
    Shahin MH; Khalifa SI; Gong Y; Hammad LN; Sallam MT; El Shafey M; Ali SS; Mohamed ME; Langaee T; Johnson JA
    Pharmacogenet Genomics; 2011 Mar; 21(3):130-5. PubMed ID: 21228733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.
    Cavallari LH; Shin J; Perera MA
    Pharmacotherapy; 2011 Dec; 31(12):1192-207. PubMed ID: 22122181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin dosing and the promise of pharmacogenomics.
    Dumas TE; Hawke RL; Lee CR
    Curr Clin Pharmacol; 2007 Jan; 2(1):11-21. PubMed ID: 18690851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.